Artiva Biotherapeutics vs Cardiff Oncology
ARTV and CRDF side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARTV and CRDF compare
Artiva Biotherapeutics is the larger company, worth 2.9 times as much as Cardiff Oncology ($189M against $65.8M).
Artiva Biotherapeutics scores higher on the StockData Score (8 against 7 for Cardiff Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARTV | CRDF |
|---|---|---|
| Size and price | ||
| Market cap | $189M | $65.8M |
| Share price | $3.86 | $0.846 |
| Change, 1 year | 18.8% | −60.3% |
| Change, 5 years | – | −84.9% |
| Beta (5Y) | 4.84 | 2.50 |
| Employees | 104 | 31 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 130× |
| P/B | 0.5× (better) | 2.5× |
| FCF yield | −40.8% | – |
| Growth | ||
| Revenue growth (TTM) | – | −7.0% |
| Revenue growth, 5Y average | – | 10.1% |
| Profitability | ||
| Operating margin | – | −8320% |
| Net margin | – | −7884% |
| Return on equity | −36.6% (better) | −94.1% |
| Return on invested capital | −3203% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 24.16 (better) | 3.30 |
| Altman Z-score | 4.16 (better) | −16.20 |
| Piotroski F-score | 1 | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 83.2% | 24.2% |
| Held by insiders | 68.3% | 4.9% |
| Insider net buying, 12 months | $106M (better) | $1.1M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 19.0% | 16.6% |
Go deeper
- ARTV stock overview
- ARTV income statement
- ARTV valuation and score
- CRDF stock overview
- CRDF income statement
- CRDF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.